If you didn't find what you were looking for, try a new search!
Zurich-Schlieren, December 5, 2014. Molecular Partners AG announces that the total offer size of the initial public offering (“IPO”) amounts to CHF 106.2 million, of which gross proceeds from the primary shares issued are CHF 104.1 million. The Joint Bookrunners of [...]
Zurich-Schlieren, November 4, 2014. Molecular Partners AG has successfully re-launched its Initial Public Offering (IPO). Due to strong interest and demand from both international and Swiss institutional and private investors, Molecular Partners accelerated the timetable and closed the bookbuilding process yesterday, [...]
Partnership will combine novel biologics (DARPins) with Roche drug-conjugate technology Basel, Switzerland / Zurich-Schlieren, Switzerland, 04 December 2013. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement [...]